MPC; rexlemestrocel-L

Cell therapy

BBoston Children's Hospital

MPC; rexlemestrocel-L is one of 5 biologic programs targeting Single ventricle. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single VentricleActive, not recruiting

Single VentriclePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Single Ventricle

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

2 2

Tracleer

Johnson & Johnson

Phase 2

3 3

Letairis

Gilead

Phase 2

1 4

Remodulin

United Therapeutics

Preclinical

—5

MPC; rexlemestrocel-L

BBoston Children's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single ventricle1 trial

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Unknown status·—·Phase 1/2·NCT03079401·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MPC; rexlemestrocel-L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MPC; rexlemestrocel-L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MPC; rexlemestrocel-L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Company: BBoston Children's Hospital

MPC; rexlemestrocel-L

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single ventricle1 trial

References

Drug Info

Quick Facts

Related News